Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy Subjects

Inclusion Criteria: * Caucasian men aged 18-55 years and ≥65 years * Women of non-childbearing potential * Japanese men aged 18-55 years * Subjects were deemed healthy on the basis of medical history, physical examination, Electrocardiogram (ECG), vital signs and safety tests of blood and urine * Subjects were able to give fully informed written consent Exclusion Criteria: * HDL-C level ≥2.59 mmol/L * Abnormal Holter ECG * Family history of long QT syndrome, hypokalaemia or Torsade de Pointes * Vital signs or 12-lead ECG values outside the acceptable range * Positive tests for hepatitis B and C, HIV 1 and 2 * Positive urine pregnancy test (women only) * Severe adverse reaction or allergy to any drug * Drug or alcohol abuse * Smoking within the 6 months before dosing with TA-8995 (Caucasian subjects), or smoking more than 10 cigarettes daily (Japanese subjects) * Over-the-counter or prescribed medication up to 7 days or 5 half-lives (whichever was longer) before dosing with TA-8995 * Consuming food or drinks containing grapefruit or cranberry within the 7 days before dosing * Participation in other clinical trials, or loss of more than 450 mL blood within the previous 3 months * Clinically relevant abnormal findings at the screening assessment * Clinically relevant abnormal medical history or concurrent medical condition * Possibility that volunteer would not cooperate